UPPSALA, Sweden, April 27, 2023 /PRNewswire/ — Focusing operations on Orexo´s strengths Q1 2023 highlights Total net revenues of SEK 158.8 m (159.4) EBITDA of SEK -41.1 m (2.8), EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK 20.9 m (32.2) Net earnings of…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.